• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Merck Announces 2016 Grant for Growth Innovation Winners


September 14, 2016

Merck (Darmstadt, Germany, known as EMD Serono in the US) this week announced the recipients of the Grant for Growth Innovation (GGI) at an award presentation European Society for Pediatric Endocrinology (ESPE) Meeting in Paris, France.   The GGI program was initiated to support the advancement of understanding of the field of growth. A total grant of up to €400,000 per year, divided between up to three research proposals, is awarded to the selected projects.    This year's winning projects are based in Australia, Italy, and Brazil, and are as follows:

  • Andrew J. Brooks
    University of Queensland Diamantina Institute, Brisbane, Australia
    Project: Targeting the transmembrane domain of the growth hormone receptor to develop new drug classes addressing unmet needs in treatment of growth hormone disorders.

  • Antonio Cittadini, MD, PhD
    Federico II University, Naples, Italy
    Project: Treatment of growth hormone deficiency associated with chronic heart failure: A randomized, double-blind, placebo-controlled study.

  • Alexander Augusto de Lima Jorge, MD, PhD
    University of São Paulo Medical School, Brazil
    Project: Growth hormone and estrogen pharmacogenetics in patients with Turner syndrome.

    For further information about the GGI and how to apply for next year's grants, please visit


Related Videos